Q1 Earnings Forecast for ALLO Issued By HC Wainwright

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – HC Wainwright issued their Q1 2026 earnings per share estimates for Allogene Therapeutics in a research note issued on Monday, June 2nd. HC Wainwright analyst R. Burns expects that the company will earn ($0.27) per share for the quarter. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Allogene Therapeutics’ Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.30) EPS and FY2026 earnings at ($1.14) EPS.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.28) EPS for the quarter, hitting the consensus estimate of ($0.28).

ALLO has been the subject of a number of other reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 target price on shares of Allogene Therapeutics in a report on Friday, March 14th. Truist Financial decreased their target price on Allogene Therapeutics from $14.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, May 14th. Robert W. Baird decreased their target price on Allogene Therapeutics from $12.00 to $9.00 and set an “outperform” rating for the company in a report on Wednesday, May 14th. Citizens Jmp lowered Allogene Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 14th. Finally, Citigroup decreased their target price on Allogene Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, May 15th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $8.44.

Allogene Therapeutics Trading Up 6.3%

NASDAQ:ALLO opened at $1.35 on Tuesday. The firm has a market cap of $295.29 million, a PE ratio of -0.87 and a beta of 0.60. The stock has a fifty day moving average price of $1.34 and a 200 day moving average price of $1.77. Allogene Therapeutics has a 12-month low of $0.86 and a 12-month high of $3.78.

Insiders Place Their Bets

In other news, CEO David D. Chang sold 46,668 shares of Allogene Therapeutics stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $1.96, for a total transaction of $91,469.28. Following the sale, the chief executive officer now owns 5,276,569 shares in the company, valued at approximately $10,342,075.24. The trade was a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 61,757 shares of company stock valued at $115,873 in the last ninety days. Insiders own 13.20% of the company’s stock.

Institutional Trading of Allogene Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ALLO. Cibc World Markets Corp acquired a new stake in shares of Allogene Therapeutics during the fourth quarter worth about $26,000. PAX Financial Group LLC acquired a new stake in shares of Allogene Therapeutics during the fourth quarter worth about $27,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Allogene Therapeutics during the first quarter worth about $28,000. RPO LLC acquired a new position in Allogene Therapeutics in the 4th quarter valued at about $31,000. Finally, Caption Management LLC acquired a new position in Allogene Therapeutics in the 4th quarter valued at about $32,000. Institutional investors and hedge funds own 83.63% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).